SAN DIEGO, May 22 /PRNewswire/ -- Victory Pharma, Inc. announced today that Dr. Shawn A. Scranton has joined the Company as Vice President of Scientific Operations. Dr. Scranton will report to Matthew Heck, President, and will serve as a member of the Company's senior executive team. "Victory is pleased to have attracted a person of Dr. Scranton's caliber, and his strategic medical knowledge signals our focus on bringing products to market and increased growth in sales," commented Mr. Heck. "As we bring more pharmaceutical products through the pipeline, Dr. Scranton's contributions will be extremely valuable." Dr. Scranton observed, "Victory Pharma's proven management team and recent commercialization successes combined with high potential products currently under development were the key reasons I decided to join the Company." Dr. Scranton brings over 15 years of drug development experience to Victory Pharma. Most recently he was Senior Director of Translational Medicine for Kalypsys, Inc., where he contributed to nonclinical, regulatory, and clinical strategies that allowed for the successful opening of NCE INDs, and conduct of subsequent Phase I clinical programs in neuropathic pain and metabolic disease. Formerly, Dr. Scranton was Director of Clinical Development and Program Director of the SDX101 program for Salmedix, Inc., which was acquired by Cephalon, Inc. in 2005. Additionally, Dr. Scranton has also held academic positions at University of the Pacific, University of Houston, and Baylor College of Medicine. Dr. Scranton will be based in the Company's corporate headquarters in San Diego, California. About Victory Pharma, Inc. Victory Pharma, Inc. is a privately held, specialty pharmaceutical company, headquartered in San Diego with sales and marketing operations in Cary, NC, focused on acquiring and marketing pain and related products. Victory markets its existing pain products through its physician based field sales force. The Company is also developing several proprietary products for treatment of chronic severe pain and commonly associated opiate induced side effects. Its lead development product is currently near completion of Phase II clinical testing in the United States. Further information regarding Victory is available at http://www.VictoryPharma.com.
SOURCE Victory Pharma, Inc.